#Branding, Strategy, #Marketing, #DigitalMarketing, Social, Mobile, Design, #contentmarketing, #fun
Greater Boston
Joined February 2009
- Tweets3K
- Following4.1K
- Followers3.3K
- Likes246
How well have you pressure-tested the assumptions behind your commercialization plan?
The problem you’re solving.
The evidence you’re building.
The traction you’re seeing.
The story you’re telling investors.
The path to adoption.
Nov 4th, MESH's @BillSchick and Katherine King French, Director of Strategy at Smith+Nephew, will lead an MDG of Boston Lunch & Learn Masterclass:
Why Great Science Still Fails
Online | November 4th | 12–1 PM ET
Register at eventbrite.com/e/why-great-s…
#MedTech #Biopharma
Some of the most expensive problems in medtech and biotech start long before an FDA submission is made.
Early-stage teams are moving fast, resources are limited & some decisions get pushed to later.
The trouble comes when “later” involves choices that become harder & expensive.
Passion for the science matters. So does knowing the problem you’re solving, who the buyer is, and what could prevent adoption.
Read Bill's newsletter where he shares 6 warning signs he’s learned to watch for after nearly 30 years working with customers in regulated industries.
Some of your company’s most useful perspectives may never make it into your marketing.
In medtech, biotech, and other technical industries, the person with the biggest title isn’t always the person with the most useful perspective for customers.
The people closest to customer problems often ask the best questions, challenge assumptions, and explain complex ideas in ways people can use.
If those voices stay out of your content, the result can become another stream of product info and familiar industry talking points.
In his latest LI newsletter, @BillSchick looks at how to identify those voices and build a process around their expertise.
Read: Who Should Be the Thought Leader for Your Company?
linkedin.com/pulse/who-shoul…
#medtech #lifesciences #founders #startups #thoughtleadership
The decisions that derail commercialization rarely look like mistakes at first.
More often, they look like reasonable assumptions—about the problem, the market, what investors need to hear, what evidence matters, and what will ultimately drive adoption.
The session combines research, market data + real-world company examples with a practical founder workbook designed to help attendees pressure-test their own plans.
The goal: spot the risks, challenge the assumptions, take action.
When: August 26th, 12–1 PM ET
Location: Online
Tickets: $10
Register at: eventbrite.com/e/why-great-s…
#MedTech #Biopharma #Commercialization
Product adoption starts long before launch.
In the latest episode of LifeSci Continuum, @BillSchick talks with @AnywhereDx co-founders Nathalya Mamane and @michaelmina_lab about building an at-home diagnostic families would actually buy and use.
They discuss:
- Starting with a real consumer problem
- Setting clear requirements before engineering begins
- Making regulated technology easier to use
- Navigating FDA, funding, and market adoption
For founders developing medical devices, diagnostics, or consumer health products, this conversation offers useful questions to consider early.
Watch the episode: youtu.be/9UcOoSVb2B0
#MedTech #ConsumerHealth #MedicalDevices #Diagnostics #LifeSciences #HealthcareInnovation
Most investor pitches contain plenty of good information.
Market size.
Product capabilities.
Growth projections.
Competitive advantages.
Then the meeting ends, and the opportunity is still hard to picture.
Use data to support the story.
Market size, traction, customer behavior, and proof points should make the opportunity easier to understand and easier to believe.
A strong pitch gives people the facts.
A strong story helps them see the opportunity, understand the timing, and remember why your company matters.
For many #startups, the opportunity is already there. The challenge is making it easy for someone else to see.
#MedTech #MedDevice #LifeSciences #MESHLife #HowToMESH
